Latest Updates

PepGen Welcomes Esteemed Neurologist Dr. John Day to Scientific Advisory Board

BOSTON, Oct. 13, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the appointment of neuromuscular neurologist John W. Day, M.D., Ph.D., to its Scientific Advisory Board. Dr. Day is a Professor of Neurology, Pediatrics (Genetics)…

PepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September

Presentations will highlight data supporting PepGen’s approach to developing treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1 BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular diseases, today announced that Chief Executive Officer James McArthur, Ph.D., will…

PepGen Announces New Additions to Leadership Team and Board of Directors

New appointments follow PepGen’s recent $112.5 million crossover financing to advance therapies for neuromuscular diseases PepGen is rapidly advancing lead programs in Duchenne muscular dystrophy and myotonic dystrophy type 1 to the clinic and growing its team in Boston, MA. BOSTON, Aug. 31, 2021 —…

PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases

Proceeds to support expansion and advancement of PepGen’s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases   BOSTON, August 5, 2021 – PepGen, Inc., a company developing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the closing of an oversubscribed $112.5 million crossover financing,…

PepGen Strengthens Leadership Team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments

– Niels Svenstrup, Ph.D., will serve as Senior Vice President of Chemistry, Manufacturing & Controls – David Pelissier, CPA, will serve as Vice President of Finance – New leaders will support PepGen in establishing its U.S. presence, building its financial strategy and advancing its pipeline BOSTON and…

PepGen to Present at Stifel’s 3rd Annual CNS Day

Boston, Mass. and Oxford, UK (March 23, 2021) – PepGen, Inc. a biotechnology company developing transformative therapies for individuals living with neuromuscular and neurologic diseases, today announced that Dr. James McArthur, CEO, will present at Stifel’s 3rd Annual CNS Day virtual conference. The presentation is scheduled for Wednesday, March 31,…

PepGen to Present Late-Breaking Data from Novel Enhanced Delivery Oligonucleotide (EDO) Pipeline at 2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference

EDO platform demonstrates potentially best-in-class safety and efficacy profile in addressing DMD and DM1 disease phenotypes; advancing rapidly to the clinic with first-in-human studies expected to initiate in early 2022 Boston, Mass. and Oxford, UK (March 15, 2021) – PepGen, an emerging biotechnology company focused on developing transformative therapies for…

PepGen Announces Formation of Scientific Advisory Board

World-renowned Neuromuscular Disease and Oligonucleotide experts Matthew Wood, M.D., Ph.D., Art Krieg, M.D., Elizabeth McNally, M.D., Ph.D., Charles Thornton, M.D., Jonathon Watts, Ph.D., and Brenda Wong, M.D., to join PepGen’s Scientific Advisory Board Boston, Mass. and Oxford, UK (February 26, 2021) – PepGen, an emerging biotechnology company focused on transforming…

PepGen Announces Appointment of James McArthur, Ph.D., as President and Chief Executive Officer

Seasoned biotech executive with deep experience and proven track record in successfully leading rare disease companies through rapid growth and development   Boston, Mass. and Oxford, UK (February 4th, 2021) – PepGen, a biotechnology company focused on transforming the care of patients with neuromuscular diseases through the enhanced…